user avatar
Mehdi Hamadani, MD
@MediHumdani
BMT & Cellular Therapy | Ex-Secretary @ASTCT | Chair @ASTCT CoPG | #bmtsm #CARTcell #lymsm | Personal views | Doctor not Provider | 🇵🇰 🏏 🇺🇸 🏈
Milwaukee, WI
Joined May 2013
Posts
  • Pinned
    user avatar
    The story of my CART pt as painted by her continues. Her latest (bottom right) shows ongoing need for neutrophils 2 years post #CART #lymsm Her prior work in thread below @MCWCancerCenter
  • user avatar
    She was septic, intubated, on 4 pressors, with post alloHCT graft failure and ANC of 0 A quick CD34 boost is what was needed to give her an outside chance Today she walked into my clinic and brought her ‘Stem Cell’ painting as a gift (my 💙 melted) #bmtsm #lymsm
  • user avatar
    I am often asked how @CIBMTR studies are not simple retrospective analyses? Following is a tweetorial re: differences in Trial vs. Registry vs. retrospective (aka real world data) data. @BldCancerDoc @Phari #bmtsm (some generalizations acknowledged)
  • user avatar
    73 year ago today, my maternal grandfather late Mustafa Ali Hamadani, announced independence of Pakistan 🇵🇰 from British rule on @RadioPakistan 🎊🎊🎊 Happy Independence Day 🇵🇰🇵🇰🇵🇰
  • user avatar
    Ready for 🇮🇳 v 🇵🇰 #T20WorldCup2021 game 🏏🏏🏏
  • user avatar
    If my alloBMT patients die, I feel personally responsible. I know it is irrational. Curiously never feel that way with non BMT cases, or even auto/CAR-T. Do other BMT tweeps feel that way? Weird form of decision guilt? Been doing BMT for a while and do realize it sounds crazy :(
  • user avatar
    This was a message sent to me by the very first patient I allografted in West Virginia in 2009 after the last elections. Brought tears to my eyes and reaffirmed my belief in the goodness of #American @DrMiguelPerales @BldCancerDoc #ShareAStoryInOneTweet x.com/DrMiguelPerale…
  • user avatar
    How a second line DLBCL trial that convincingly changes SOC could have been designed 👇 SOC should been current ‘actual’ standard ie auto for chemosensitive and CAR for <PR to 2nd line vs. CAR for everyone & OS as primary endpoint ⬅️⬅️ #ash21 #lymsm #bmtsm
  • user avatar
    I have not attended as many #ASH20 sessions, since I was a fellow. I think, the online feature needs to stay. Will reduce physical conference foot print, better for environment, save 💵💰💸. Raise you hand if you agree? @BldCancerDoc @szusmani @StephanieLeeMD @graham74GC @Phari
    GIF
  • user avatar
    👇👇👇 bound to generate a lot of opinion but we finally have some data #bmtsm #lymSM @CIBMTR Autologous Transplant vs CAR-T for Relapsed DLBCL in PR led by @mshadman | @BloodJournal | Tweetorial ***1/8 ashpublications.org/blood/article/…
  • user avatar
    My go to #GvHD hacks Ref GI = Rux Ref skin esp ch = ECP Transaminitis = MMF Early BO = ECP Adv BO = belumosodil Tac tox = siro Ref bili = looking for one Share yours 👇👇👇 #bmtsm
  • user avatar
    Thiotepa 🗝️ component of autoHCT conditioning in Primary CNS 🧠lymphoma. Its a tie between BCNU/TT vs. Bu/Cy/TT #lymsm @MScordoMD Drs. Sauter & Wang in collaboration with @CIBMTR ja.ma/2SyDUcX via @JAMAOnc part of @JAMANetwork #bmtsm
  • user avatar
    If you see an eligible DLBCL patient in CR, does #CART outperform AutoHCT? Only available data by @CIBMTR @mshadman Reminds you to keep an open mind, one size does not fit all 🙏🙏 @ASH_hematology for recognizing our work in Press Release #ASH23
  • user avatar
    Why do some institutions insist on differentiating between let’s say An Assistant Prof vs a ‘clinical’ assistant Prof? Often a tacit hint that ‘clinical’ is less glorious, when the latter is what keeps health system profitable Things that bother me….. #MedEd #MedTwitter